biostudies-literatureUnknown24(1)Yang MH<h4>Background</h4>In recent years, the addition of cetuximab to chemotherapy has improved treatment outcomes for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). In this study, we present the real-world survival data of R/M HNSCC patients who received cetuximab-containing regimens from thirteen medical centers in Taiwan, as well as a three-level risk stratification model for this patient population.<h4>Methods</h4>This study enrolled R/M HNSCC patients from thirteen medical centers in Taiwan who received cetuximab-containing regimens from January 1, 2017 to June 6, 2022. The cases were divided into a training cohort and a validation cohort based on the start of treatment. Overall survival (OS) was evaluated in both cohorts and exploratory analysis was BMC cancer1227https://www.ebi.ac.uk/biostudies/studies/S-EPMC11452986biostudies-literaturePrognostic factors and risk-stratification model of recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regimen.PMC11452986Chang YFLin JCWang HMChen JPYen CJLu WCLou PJHua CHChien CYYiu CYLien MYLin CLYang MHHsieh JCWu SYHsieh MCWang HCHuang TLChu PYWang CCChen THLu HJHuang HCLiu YCfalsePrognostic factors and risk-stratification model of recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regimen.<h4>Background</h4>In recent years, the addition of cetuximab to chemotherapy has improved treatment outcomes for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). In this study, we present the real-world survival data of R/M HNSCC patients who received cetuximab-containing regimens from thirteen medical centers in Taiwan, as well as a three-level risk stratification model for this patient population.<h4>Methods</h4>This study enrolled R/M HNSCC patients from thirteen medical centers in Taiwan who received cetuximab-containing regimens from January 1, 2017 to June 6, 2022. The cases were divided into a training cohort and a validation cohort based on the start of treatment. Overall survival (OS) was evaluated in both cohorts and exploratory analysis was 2024-01-01T00:00:00Z2024 Oct2026-06-07T08:06:52.292Z2025-04-04T02:05:05.92ZS-EPMC114529863936918910.1186/s12885-024-12425-0